×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
LON:OXB

Oxford Biomedica Share Forecast, Price & News

GBX 481.50
+0.50 (+0.10%)
(As of 06/27/2022 11:27 AM ET)
Add
Compare
Today's Range
479.50
491.50
50-Day Range
420
650
52-Week Range
414
1,678
Volume
21,739 shs
Average Volume
176,340 shs
Market Capitalization
£462.59 million
P/E Ratio
21.69
Dividend Yield
N/A
Price Target
GBX 1,687.50
30 days | 90 days | 365 days | Advanced Chart

Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

OXB Stock Forecast (MarketRank)

Overall MarketRank

2.04 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Oxford Biomedica logo

About Oxford Biomedica (LON:OXB)

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

OXB Stock News Headlines

1 FTSE 250 to buy for long-term growth
Virica Biotech Announces R&D Partnership With...
Oxford Biomedica CEO John Dawson to retire
John Dawson to retire from Oxford Biomedica
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
744
Year Founded
N/A

Company Calendar

Today
6/27/2022
Next Earnings (Estimated)
9/20/2022

Price Target and Rating

Average Stock Price Forecast
GBX 1,687.50
High Stock Price Forecast
GBX 2,150
Low Stock Price Forecast
GBX 1,070
Forecasted Upside/Downside
+250.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£142.80 million
Cash Flow
GBX 129.46 per share
Book Value
GBX 217.40 per share

Miscellaneous

Free Float
N/A
Market Cap
£462.59 million
Optionable
Not Optionable
Beta
N/A














Oxford Biomedica Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oxford Biomedica stock.
View analyst ratings for Oxford Biomedica
or view top-rated stocks.

What is Oxford Biomedica's stock price forecast for 2022?

4 brokers have issued twelve-month target prices for Oxford Biomedica's shares. Their OXB stock forecasts range from GBX 1,070 to GBX 2,150. On average, they predict Oxford Biomedica's share price to reach GBX 1,687.50 in the next year. This suggests a possible upside of 250.5% from the stock's current price.
View analysts' price targets for Oxford Biomedica
or view top-rated stocks among Wall Street analysts.

How has Oxford Biomedica's stock performed in 2022?

Oxford Biomedica's stock was trading at GBX 1,230 at the beginning of 2022. Since then, OXB shares have decreased by 60.9% and is now trading at GBX 481.50.
View the best growth stocks for 2022 here
.

When is Oxford Biomedica's next earnings date?

Oxford Biomedica is scheduled to release its next quarterly earnings announcement on Tuesday, September 20th 2022.
View our earnings forecast for Oxford Biomedica
.

Who are Oxford Biomedica's key executives?

Oxford Biomedica's management team includes the following people:
  • Dr. Roch Doliveux, Interim CEO & Chairman
  • Mr. Stuart Paynter, CFO, Company Sec. & Director (Age 48, Pay $755k)
  • Mr. Nick Page, Chief Operations Officer
  • Dr. James Miskin Ph.D., Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D., Chief Scientific Officer
  • Mr. Matthew Treagus, Chief Information Officer
  • Sophia Bolhassan, Head of Investor Relations
  • Ms. Natalie Louise Walter, Gen. Counsel
  • Dr. Jason Slingsby MBA, Chief Bus. & Corp. Devel. Officer
  • Ms. Sarah Macleod, Head of Communications

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

How do I buy shares of Oxford Biomedica?

Shares of OXB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oxford Biomedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 481.50.

How much money does Oxford Biomedica make?

Oxford Biomedica (LON:OXB) has a market capitalization of £462.59 million and generates £142.80 million in revenue each year.

How many employees does Oxford Biomedica have?

Oxford Biomedica employs 744 workers across the globe.

How can I contact Oxford Biomedica?

Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000.

This page (LON:OXB) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.